{"id":9502,"date":"2024-11-25T00:00:00","date_gmt":"2024-11-25T04:00:00","guid":{"rendered":"https:\/\/livingstagenew.wpenginepowered.com\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/"},"modified":"2026-06-25T11:06:59","modified_gmt":"2026-06-25T15:06:59","slug":"niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh","status":"publish","type":"transaction","link":"https:\/\/livingstonepartners.com\/de\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/","title":{"rendered":"Niterra Ventures Company investiert weitere 18 Millionen US-Dollar in neoplas med GmbH"},"content":{"rendered":"\n<p><strong>Das Healthcare-Team von Livingstone in D\u00fcsseldorf setzt seine Beratungst\u00e4tigkeit f\u00fcr die <\/strong><a target=\"_blank\" rel=\"noopener noreferrer\" href=\"https:\/\/neoplas-med.eu\/\"><strong>neoplas med GmbH<\/strong><\/a><strong> in der dritten Finanzierungsrunde fort. Der in Greifswald ans\u00e4ssige Pionier der Medizintechnologie intensiviert seine strategische Zusammenarbeit mit <\/strong><a target=\"_blank\" rel=\"noopener noreferrer\" href=\"https:\/\/niterraventures.com\/\"><strong>Niterra Ventures Company<\/strong><\/a><strong> durch eine Kapitalerh\u00f6hung von 18 Millionen US-Dollar, um den Markt f\u00fcr seine innovativen Wundversorgungstechnologien weiter auszubauen. Mit einer Gesamtinvestition von 25 Millionen US-Dollar hatte Niterra Ventures Company bereits in den Jahren 2022 und 2023 in neoplas med investiert.<\/strong><\/p><p>neoplas med, ein Spin-off des Leibniz-Instituts f\u00fcr Plasmaforschung und Technologie e.V. (INP), hat den Argon-Kaltplasma-Jet kINPen\u00ae MED entwickelt, einen innovativen \u201ePlasma-Stift\u201c, der einen pr\u00e4zisen Plasmastrahl auf Wunden richtet und die Wundheilung erheblich beschleunigt. Klinische Studien zeigen, dass die Behandlungsdauer im Vergleich zu herk\u00f6mmlichen Methoden um 50 Prozent verk\u00fcrzt werden kann \u2013 ohne Nebenwirkungen oder die Entwicklung von Resistenzen. neoplas med ist eines der wenigen Unternehmen, das das Inertgas Argon f\u00fcr diese nahezu schmerzfreie und schnelle Therapie nutzt, die sowohl infizierte als auch chronische Wunden behandelt. Mit seinem \u201ePlasma-Stift\u201c ist neoplas med GmbH der einzige Hersteller von Kaltplasma-Produkten in Europa, der nach der europ\u00e4ischen Medizinprodukteverordnung (MDR) zertifiziert ist.<\/p><p><em>\u201eDie Folgeinvestition von Niterra Ventures Company er\u00f6ffnet uns v\u00f6llig neue M\u00f6glichkeiten, weitere M\u00e4rkte zu erschlie\u00dfen, unsere Technologieplattform auszubauen und neue Produkte zu entwickeln\u201c, <\/em>sagt <strong>Ulrike Sailer, CEO von neoplas med<\/strong><em>. \u201eWir machen nicht nur einen gro\u00dfen Schritt nach vorne, sondern sichern und schaffen auch neue Arbeitspl\u00e4tze im High-Tech-Sektor.\u201c<\/em><\/p><p>In Deutschland nutzen 75 Prozent der Universit\u00e4tskliniken sowie zahlreiche Arztpraxen und Krankenh\u00e4user die patentierte Argon-Jet-Kaltplasmatherapie von neoplas med, die weltweit bereits in mehr als 500.000 Behandlungen angewendet wurde, darunter in f\u00fchrenden Kliniken im Nahen Osten. Die Mittel aus dieser Finanzierung dienen der Weiterentwicklung der Technologieplattform und der Expansion der internationalen Gesch\u00e4ftst\u00e4tigkeiten, mit einem besonderen Fokus auf die USA, Europa und den Nahen Osten.<\/p><p><em>\u201eNiterra Ventures Company erschlie\u00dft neue Gesch\u00e4ftsm\u00f6glichkeiten in den Bereichen Medizin, Cleantech, Energie und IoT, um die Lebensqualit\u00e4t mit bahnbrechenden Technologien zu verbessern\u201c, <\/em>sagt <strong>Dirk Schapeler, Pr\u00e4sident von Niterra Ventures Company<\/strong>. \u201e<em>Wir arbeiten seit mehreren Jahren eng mit neoplas med zusammen und sind begeistert von den positiven Auswirkungen des Argon-Kaltplasma kINPens auf die Patienten. Daher war unsere Folgeinvestition ein logischer Schritt.\u201c<\/em><\/p><p>Im Rahmen seiner Aktivit\u00e4ten im medizinischen Bereich investiert Niterra Ventures Company in Technologien zur Diagnose und Beurteilung von Erkrankungen in den Bereichen Kardiologie, Onkologie, Neurologie und Bluthochdruck.<\/p><p><em>\u201eWir freuen uns, neoplas med bei ihrem ambitionierten Wachstumskurs zu unterst\u00fctzen und das Erreichen neuer Meilensteine und den weiteren Erfolg zu erm\u00f6glichen. Die Kaltplasmatechnologie von neoplas med stellt einen wesentlichen Fortschritt im Gesundheitssektor dar und bietet innovative L\u00f6sungen, die die Wirksamkeit von Behandlungen und die Patientenversorgung in zahlreichen medizinischen Disziplinen verbessern\u201c,<\/em> sagt <a rel=\"noopener noreferrer\" href=\"https:\/\/livingstonepartners.com\/de\/team\/dr-ralf-nowak\/\"><strong>Dr. Ralf Nowak, Partner bei Livingstone<\/strong><\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Livingstone ber\u00e4t neoplas med exklusiv in der dritten Finanzierungsrunde \u2013 nach erfolgreichen Runden in den Jahren 2022 und 2023<\/p>\n","protected":false},"featured_media":2275,"template":"","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"client-type":[],"region":[],"sector":[],"service":[],"transaction-type":[],"class_list":["post-9502","transaction","type-transaction","status-publish","has-post-thumbnail","hentry"],"acf":{"team_members":[1332,1315],"date":"20241125","client_type":43,"type":[1039],"region":[385,379],"services":[443],"sectors":[693,702],"related_transactions":"","related_testimonials":[51734,51735,51736],"contacts":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Niterra Ventures Company investiert weitere 18 Millionen US-Dollar in neoplas med GmbH - Livingstone Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/livingstonepartners.com\/de\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Niterra Ventures Company investiert weitere 18 Millionen US-Dollar in neoplas med GmbH - Livingstone Partners\" \/>\n<meta property=\"og:description\" content=\"Livingstone ber\u00e4t neoplas med exklusiv in der dritten Finanzierungsrunde \u2013 nach erfolgreichen Runden in den Jahren 2022 und 2023\" \/>\n<meta property=\"og:url\" content=\"https:\/\/livingstonepartners.com\/de\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/\" \/>\n<meta property=\"og:site_name\" content=\"Livingstone Partners\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-25T15:06:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/livingstonepartners.com\/wp-content\/uploads\/2026\/05\/65c7c708.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/de\\\/transaction\\\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\\\/\",\"url\":\"https:\\\/\\\/livingstonepartners.com\\\/de\\\/transaction\\\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\\\/\",\"name\":\"Niterra Ventures Company investiert weitere 18 Millionen US-Dollar in neoplas med GmbH - Livingstone Partners\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/de\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/de\\\/transaction\\\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/de\\\/transaction\\\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/livingstonepartners.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/65c7c708.png\",\"datePublished\":\"2024-11-25T04:00:00+00:00\",\"dateModified\":\"2026-06-25T15:06:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/de\\\/transaction\\\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/livingstonepartners.com\\\/de\\\/transaction\\\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/de\\\/transaction\\\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\\\/#primaryimage\",\"url\":\"https:\\\/\\\/livingstonepartners.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/65c7c708.png\",\"contentUrl\":\"https:\\\/\\\/livingstonepartners.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/65c7c708.png\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/de\\\/transaction\\\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Homepage\",\"item\":\"https:\\\/\\\/livingstonepartners.com\\\/de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Transactions\",\"item\":\"https:\\\/\\\/livingstonepartners.com\\\/de\\\/transaction\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Niterra Ventures Company investiert weitere 18 Millionen US-Dollar in neoplas med GmbH\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/de\\\/#website\",\"url\":\"https:\\\/\\\/livingstonepartners.com\\\/de\\\/\",\"name\":\"Livingstone Partners\",\"description\":\"Deals Done Right.\",\"publisher\":{\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/livingstonepartners.com\\\/de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/de\\\/#organization\",\"name\":\"Livingstone Partners\",\"url\":\"https:\\\/\\\/livingstonepartners.com\\\/de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/livingstonepartners.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/logo_livingstone.svg\",\"contentUrl\":\"https:\\\/\\\/livingstonepartners.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/logo_livingstone.svg\",\"caption\":\"Livingstone Partners\"},\"image\":{\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Niterra Ventures Company investiert weitere 18 Millionen US-Dollar in neoplas med GmbH - Livingstone Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/livingstonepartners.com\/de\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/","og_locale":"de_DE","og_type":"article","og_title":"Niterra Ventures Company investiert weitere 18 Millionen US-Dollar in neoplas med GmbH - Livingstone Partners","og_description":"Livingstone ber\u00e4t neoplas med exklusiv in der dritten Finanzierungsrunde \u2013 nach erfolgreichen Runden in den Jahren 2022 und 2023","og_url":"https:\/\/livingstonepartners.com\/de\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/","og_site_name":"Livingstone Partners","article_modified_time":"2026-06-25T15:06:59+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/livingstonepartners.com\/wp-content\/uploads\/2026\/05\/65c7c708.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/livingstonepartners.com\/de\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/","url":"https:\/\/livingstonepartners.com\/de\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/","name":"Niterra Ventures Company investiert weitere 18 Millionen US-Dollar in neoplas med GmbH - Livingstone Partners","isPartOf":{"@id":"https:\/\/livingstonepartners.com\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/livingstonepartners.com\/de\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/#primaryimage"},"image":{"@id":"https:\/\/livingstonepartners.com\/de\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/#primaryimage"},"thumbnailUrl":"https:\/\/livingstonepartners.com\/wp-content\/uploads\/2026\/05\/65c7c708.png","datePublished":"2024-11-25T04:00:00+00:00","dateModified":"2026-06-25T15:06:59+00:00","breadcrumb":{"@id":"https:\/\/livingstonepartners.com\/de\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/livingstonepartners.com\/de\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/livingstonepartners.com\/de\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/#primaryimage","url":"https:\/\/livingstonepartners.com\/wp-content\/uploads\/2026\/05\/65c7c708.png","contentUrl":"https:\/\/livingstonepartners.com\/wp-content\/uploads\/2026\/05\/65c7c708.png","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/livingstonepartners.com\/de\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Homepage","item":"https:\/\/livingstonepartners.com\/de\/"},{"@type":"ListItem","position":2,"name":"Transactions","item":"https:\/\/livingstonepartners.com\/de\/transaction\/"},{"@type":"ListItem","position":3,"name":"Niterra Ventures Company investiert weitere 18 Millionen US-Dollar in neoplas med GmbH"}]},{"@type":"WebSite","@id":"https:\/\/livingstonepartners.com\/de\/#website","url":"https:\/\/livingstonepartners.com\/de\/","name":"Livingstone Partners","description":"Deals Done Right.","publisher":{"@id":"https:\/\/livingstonepartners.com\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/livingstonepartners.com\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/livingstonepartners.com\/de\/#organization","name":"Livingstone Partners","url":"https:\/\/livingstonepartners.com\/de\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/livingstonepartners.com\/de\/#\/schema\/logo\/image\/","url":"https:\/\/livingstonepartners.com\/wp-content\/uploads\/2026\/05\/logo_livingstone.svg","contentUrl":"https:\/\/livingstonepartners.com\/wp-content\/uploads\/2026\/05\/logo_livingstone.svg","caption":"Livingstone Partners"},"image":{"@id":"https:\/\/livingstonepartners.com\/de\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/livingstonepartners.com\/de\/wp-json\/wp\/v2\/transaction\/9502","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/livingstonepartners.com\/de\/wp-json\/wp\/v2\/transaction"}],"about":[{"href":"https:\/\/livingstonepartners.com\/de\/wp-json\/wp\/v2\/types\/transaction"}],"version-history":[{"count":1,"href":"https:\/\/livingstonepartners.com\/de\/wp-json\/wp\/v2\/transaction\/9502\/revisions"}],"predecessor-version":[{"id":70902,"href":"https:\/\/livingstonepartners.com\/de\/wp-json\/wp\/v2\/transaction\/9502\/revisions\/70902"}],"acf:post":[{"embeddable":true,"href":"https:\/\/livingstonepartners.com\/de\/wp-json\/wp\/v2\/testimonial\/51736"},{"embeddable":true,"href":"https:\/\/livingstonepartners.com\/de\/wp-json\/wp\/v2\/testimonial\/51735"},{"embeddable":true,"href":"https:\/\/livingstonepartners.com\/de\/wp-json\/wp\/v2\/testimonial\/51734"},{"embeddable":true,"href":"https:\/\/livingstonepartners.com\/de\/wp-json\/wp\/v2\/team-member\/1315"},{"embeddable":true,"href":"https:\/\/livingstonepartners.com\/de\/wp-json\/wp\/v2\/team-member\/1332"}],"acf:term":[{"embeddable":true,"taxonomy":"sector","href":"https:\/\/livingstonepartners.com\/de\/wp-json\/wp\/v2\/sector\/702"},{"embeddable":true,"taxonomy":"sector","href":"https:\/\/livingstonepartners.com\/de\/wp-json\/wp\/v2\/sector\/693"},{"embeddable":true,"taxonomy":"service","href":"https:\/\/livingstonepartners.com\/de\/wp-json\/wp\/v2\/service\/443"},{"embeddable":true,"taxonomy":"region","href":"https:\/\/livingstonepartners.com\/de\/wp-json\/wp\/v2\/region\/379"},{"embeddable":true,"taxonomy":"region","href":"https:\/\/livingstonepartners.com\/de\/wp-json\/wp\/v2\/region\/385"},{"embeddable":true,"taxonomy":"transaction-type","href":"https:\/\/livingstonepartners.com\/de\/wp-json\/wp\/v2\/transaction-type\/1039"},{"embeddable":true,"taxonomy":"client-type","href":"https:\/\/livingstonepartners.com\/de\/wp-json\/wp\/v2\/client-type\/43"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/livingstonepartners.com\/de\/wp-json\/wp\/v2\/media\/2275"}],"wp:attachment":[{"href":"https:\/\/livingstonepartners.com\/de\/wp-json\/wp\/v2\/media?parent=9502"}],"wp:term":[{"taxonomy":"client-type","embeddable":true,"href":"https:\/\/livingstonepartners.com\/de\/wp-json\/wp\/v2\/client-type?post=9502"},{"taxonomy":"region","embeddable":true,"href":"https:\/\/livingstonepartners.com\/de\/wp-json\/wp\/v2\/region?post=9502"},{"taxonomy":"sector","embeddable":true,"href":"https:\/\/livingstonepartners.com\/de\/wp-json\/wp\/v2\/sector?post=9502"},{"taxonomy":"service","embeddable":true,"href":"https:\/\/livingstonepartners.com\/de\/wp-json\/wp\/v2\/service?post=9502"},{"taxonomy":"transaction-type","embeddable":true,"href":"https:\/\/livingstonepartners.com\/de\/wp-json\/wp\/v2\/transaction-type?post=9502"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}